<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; cheapest</title>
	<atom:link href="http://www.tapanray.in/tag/cheapest/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Price Control in India: When A Local Media Goes Against, A Global CEO Doesn’t</title>
		<link>http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt</link>
		<comments>http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/#comments</comments>
		<pubDate>Sun, 13 Nov 2016 23:40:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[AIDAN]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[cheapest]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[demonetization]]></category>
		<category><![CDATA[Donald]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Economic Times]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Estate]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Forty]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[gratification]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7963</guid>
		<description><![CDATA[‘Variety is the spice of life’, as the good old saying goes. The week, just gone by, was indeed packed with a wide variety of surprises, well encompassing various important areas, some of which are as follows: Effective November 08, &#8230; <a href="http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Price Control in India: A Fresh Advocacy With Blunt Edges</title>
		<link>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges</link>
		<comments>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/#comments</comments>
		<pubDate>Mon, 07 Sep 2015 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[blunt]]></category>
		<category><![CDATA[campaign]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[cheapest]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[cutting]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[edges]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[income]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[parity]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pharmasofttech]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[purchasing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Yeh dil maange more]]></category>
		<category><![CDATA[“Assessing the Impact of Price Control Measures on Access to Medicines in India”]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7017</guid>
		<description><![CDATA[It is no-brainer that the advocacy initiatives to influence the new Government doing away with the ‘Drug Price Control’ in India has re-started by flooring the gas pedal. A fresh invigorating effort, apparently a pretty expensive one, has been initiated &#8230; <a href="http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In the quagmire of Pharmaceutical Pricing</title>
		<link>http://www.tapanray.in/in-the-quagmire-of-pharmaceutical-pricing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-quagmire-of-pharmaceutical-pricing</link>
		<comments>http://www.tapanray.in/in-the-quagmire-of-pharmaceutical-pricing/#comments</comments>
		<pubDate>Mon, 16 May 2011 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[BPL]]></category>
		<category><![CDATA[cheapest]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[quagmire]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=258</guid>
		<description><![CDATA[Pricing of Pharmaceutical Products has now become one of the most complex and sensitive areas of the business, like never before. This is mainly because of the concern on the impact of medicine prices to access of medicines, especially, in &#8230; <a href="http://www.tapanray.in/in-the-quagmire-of-pharmaceutical-pricing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-quagmire-of-pharmaceutical-pricing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
